Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.79 EUR | +1.04% | +8.34% | +82.01% |
May. 28 | OSE Immuno: up on analysts' comments | CF |
May. 28 | Invest Securities Lifts OSE Immuno PT, Maintains at Buy | MT |
Sales 2023 | 2.23M 2.42M | Sales 2024 * | 37.83M 41.08M | Capitalization | 169M 184M |
---|---|---|---|---|---|
Net income 2023 | -23M -24.97M | Net income 2024 * | -5M -5.43M | EV / Sales 2023 | 36.2 x |
Net Debt 2023 * | 33.7M 36.6M | Net Debt 2024 * | 46.6M 50.6M | EV / Sales 2024 * | 5.7 x |
P/E ratio 2023 |
-3.63
x | P/E ratio 2024 * |
-18.1
x | Employees | 62 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 72.4% |
Latest transcript on OSE Immunotherapeutics
1 day | +1.04% | ||
1 week | +8.34% | ||
Current month | +38.12% | ||
1 month | +40.11% | ||
3 months | +135.70% | ||
6 months | +91.40% | ||
Current year | +82.01% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 69 | 04-11-16 | |
Nicolas Poirier
CEO | Chief Executive Officer | 42 | 16-05-30 |
Director of Finance/CFO | - | 16-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 69 | 04-11-16 | |
Director/Board Member | 66 | 23-06-21 | |
Director/Board Member | 66 | 22-02-17 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 7.79 | +1.04% | 161,362 |
24-05-27 | 7.71 | -4.81% | 212,291 |
24-05-24 | 8.1 | -3.11% | 172,140 |
24-05-23 | 8.36 | +0.36% | 248,992 |
24-05-22 | 8.33 | +14.74% | 781,168 |
Real-time Euronext Paris, May 28, 2024 at 11:35 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+82.01% | 182M | |
+54.05% | 63.85B | |
-2.02% | 41.83B | |
+40.01% | 40.47B | |
-10.22% | 27.17B | |
+13.42% | 26.52B | |
-21.60% | 18.69B | |
+2.89% | 12.73B | |
+22.40% | 12.11B | |
+27.49% | 12.07B |
- Stock Market
- Equities
- OSE Stock